ATE224721T1 - Verfahren zur verbesserung der bioverfügbarkeit des fexofenadins und seiner derivate - Google Patents

Verfahren zur verbesserung der bioverfügbarkeit des fexofenadins und seiner derivate

Info

Publication number
ATE224721T1
ATE224721T1 AT98935892T AT98935892T ATE224721T1 AT E224721 T1 ATE224721 T1 AT E224721T1 AT 98935892 T AT98935892 T AT 98935892T AT 98935892 T AT98935892 T AT 98935892T AT E224721 T1 ATE224721 T1 AT E224721T1
Authority
AT
Austria
Prior art keywords
fexofenadine
bioavailability
derivatives
improving
Prior art date
Application number
AT98935892T
Other languages
German (de)
English (en)
Inventor
Kin-Kai Hwang
Dennis H Giesing
Gail H Hurst
Original Assignee
Aventis Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Inc filed Critical Aventis Pharma Inc
Application granted granted Critical
Publication of ATE224721T1 publication Critical patent/ATE224721T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/745—Polymers of hydrocarbons
    • A61K31/75—Polymers of hydrocarbons of ethene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/765—Polymers containing oxygen
    • A61K31/77—Polymers containing oxygen of oxiranes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
AT98935892T 1997-08-14 1998-07-21 Verfahren zur verbesserung der bioverfügbarkeit des fexofenadins und seiner derivate ATE224721T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US91156397A 1997-08-14 1997-08-14
PCT/US1998/015098 WO1999008690A1 (en) 1997-08-14 1998-07-21 Method of enhancing bioavailability of fexofenadine and its derivatives

Publications (1)

Publication Number Publication Date
ATE224721T1 true ATE224721T1 (de) 2002-10-15

Family

ID=25430473

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98935892T ATE224721T1 (de) 1997-08-14 1998-07-21 Verfahren zur verbesserung der bioverfügbarkeit des fexofenadins und seiner derivate

Country Status (29)

Country Link
EP (1) EP1003528B1 (enExample)
JP (1) JP4295913B2 (enExample)
KR (1) KR100522985B1 (enExample)
CN (1) CN1143680C (enExample)
AR (1) AR018505A1 (enExample)
AT (1) ATE224721T1 (enExample)
AU (1) AU725965C (enExample)
BR (1) BR9811937A (enExample)
CA (1) CA2301267C (enExample)
CZ (1) CZ293666B6 (enExample)
DE (1) DE69808303T2 (enExample)
DK (1) DK1003528T3 (enExample)
EE (1) EE04263B1 (enExample)
ES (1) ES2179523T3 (enExample)
HU (1) HU226823B1 (enExample)
ID (1) ID24463A (enExample)
IL (1) IL134521A (enExample)
NO (1) NO325148B1 (enExample)
NZ (1) NZ502133A (enExample)
OA (1) OA11287A (enExample)
PL (1) PL191607B1 (enExample)
PT (1) PT1003528E (enExample)
RU (1) RU2197967C2 (enExample)
SK (1) SK283868B6 (enExample)
TR (1) TR200000419T2 (enExample)
TW (1) TWI240633B (enExample)
UA (1) UA64765C2 (enExample)
WO (1) WO1999008690A1 (enExample)
ZA (1) ZA987221B (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69624559T2 (de) 1995-02-28 2003-07-10 Aventis Pharmaceuticals Inc., Bridgewater Arzneizubereitungen für piperidinalkanolderivate
EP0998272B1 (en) * 1997-08-26 2003-05-02 Aventis Pharmaceuticals Inc. Pharmaceutical composition for combination of piperidinoalkanol-decongestant
GB9822170D0 (en) * 1998-10-13 1998-12-02 Danbioyst Uk Ltd Novel formulations of fexofenadine
WO2003101437A2 (en) * 2002-05-29 2003-12-11 Aventis Pharmaceuticals Holdings Inc. Method of treating asthma using fexofenadine
GB0319935D0 (en) * 2003-08-26 2003-09-24 Cipla Ltd Polymorphs
PE20060416A1 (es) * 2004-08-03 2006-06-09 Novartis Ag Composicion de inhibidores de renina e inhibidores de proteinas de efusion
JP2008120684A (ja) * 2005-03-07 2008-05-29 Kumamoto Univ 抗アレルギー薬
KR101106374B1 (ko) 2009-06-05 2012-01-19 민병욱 고체연료에 의한 가연성 가스 발생 장치
KR101117014B1 (ko) * 2009-09-09 2012-06-14 민병욱 부패성 폐기물의 바이오매스 처리에 의한 폐자원 재활용 방법 및 장치
CN101843616B (zh) * 2010-06-04 2011-07-27 西安万隆制药有限责任公司 一种盐酸非索非那定与微晶纤维素组合物及其制备方法
RU2453315C2 (ru) * 2010-08-17 2012-06-20 Открытое акционерное общество "Химико-фармацевтический комбинат "АКРИХИН" (ОАО "АКРИХИН") Фармацевтическая композиция для лечения аллергических заболеваний
EA201391742A1 (ru) 2011-05-20 2014-04-30 Авентис Фармасьютикалз Инк. Фармацевтическая композиция, включающая фексофенадин
RU2504018C1 (ru) * 2012-05-28 2014-01-10 Государственное бюджетное образовательное учреждение высшего профессионального образования "Рязанский государственный медицинский университет имени академика И.П. Павлова" Министерства здравоохранения и социального развития Российской Федерации Способ моделирования состояния индукции функциональной активности гликопротеина-р финастеридом в эксперименте
RU2553362C1 (ru) * 2014-01-09 2015-06-10 Государственное бюджетное образовательное учреждение высшего профессионального образования "Рязанский государственный медицинский университет имени академика И.П. Павлова" Министерства здравоохранения Российской Федерации Способ моделирования состояния ингибирования функциональной активности гликопротеина-р линестренолом в эксперименте
CN104188998A (zh) * 2014-09-18 2014-12-10 中山大学 一种柚皮苷与盐酸非索非那丁药物组合物及其制剂

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4254129A (en) * 1979-04-10 1981-03-03 Richardson-Merrell Inc. Piperidine derivatives
NO900427L (no) * 1989-01-31 1990-08-01 Int Pharma Agentur Erosjonsregulert frigjoeringssystem for aktive stoffer og en fremgangsmaate for deres fremstilling.
US5567592A (en) * 1994-02-02 1996-10-22 Regents Of The University Of California Screening method for the identification of bioenhancers through the inhibition of P-glycoprotein transport in the gut of a mammal
CA2224227A1 (en) * 1995-06-07 1996-12-19 Avmax, Inc. Use of essential oils to increase bioavailability of oral pharmaceutical compounds
AU5893796A (en) * 1995-06-07 1996-12-30 Novo Nordisk A/S Modification of polypeptides

Also Published As

Publication number Publication date
NO20000706L (no) 2000-04-13
CZ293666B6 (cs) 2004-06-16
EP1003528A1 (en) 2000-05-31
RU2197967C2 (ru) 2003-02-10
ZA987221B (en) 1999-02-15
DE69808303D1 (de) 2002-10-31
SK1842000A3 (en) 2000-08-14
HU226823B1 (hu) 2009-11-30
NZ502133A (en) 2002-03-28
IL134521A0 (en) 2001-04-30
UA64765C2 (uk) 2004-03-15
WO1999008690A1 (en) 1999-02-25
DK1003528T3 (da) 2003-02-03
PL191607B1 (pl) 2006-06-30
CN1267221A (zh) 2000-09-20
HK1025901A1 (en) 2000-12-01
EE200000069A (et) 2000-10-16
CA2301267A1 (en) 1999-02-25
PL338579A1 (en) 2000-11-06
JP4295913B2 (ja) 2009-07-15
KR100522985B1 (ko) 2005-10-21
CN1143680C (zh) 2004-03-31
SK283868B6 (sk) 2004-03-02
BR9811937A (pt) 2000-09-05
CZ2000522A3 (cs) 2000-09-13
DE69808303T2 (de) 2003-05-22
ID24463A (id) 2000-07-20
EP1003528B1 (en) 2002-09-25
AU725965B2 (en) 2000-10-26
OA11287A (en) 2003-10-22
NO20000706D0 (no) 2000-02-11
AU8505098A (en) 1999-03-08
AU725965C (en) 2004-04-22
TR200000419T2 (tr) 2000-09-21
HUP0003189A2 (en) 2001-03-28
EE04263B1 (et) 2004-04-15
KR20010022845A (ko) 2001-03-26
AR018505A1 (es) 2001-11-28
PT1003528E (pt) 2003-02-28
HUP0003189A3 (en) 2001-04-28
JP2001515041A (ja) 2001-09-18
CA2301267C (en) 2004-07-13
NO325148B1 (no) 2008-02-11
TWI240633B (en) 2005-10-01
ES2179523T3 (es) 2003-01-16
IL134521A (en) 2005-07-25

Similar Documents

Publication Publication Date Title
EP0981640A4 (en) Methods for drug target screening
DE60039177D1 (de) Verfahren zur verbesserung der haut und des pelzes von haustieren
DE60210265D1 (de) Verfahren und zwischenprodukte zur herstellung von 4-aminochinolin-cetp-inhibitoren
EP1014995A4 (en) COMPOSITIONS AND METHODS FOR PREVENTING RESTENOSES CONSECUTIVE TO REVASCULARIZATION INTERVENTIONS
DE60027405D1 (de) Verfahren zur steigerung der aktivität von haustieren
DE60141062D1 (de) Kreuzpolarisationsinterferenzkompensator und Verfahren zur Kompensation der Kreuzpolarisationsinterferenz
DE69913047D1 (de) Verfahren zur Herstellung von Benzamid-Derivaten
DE69717413D1 (de) Verfahren zur Gewichtsbestimmung von bogenförmigen Trägern
DE69534416D1 (de) Verfahren und formulierungen zur bekämpfung von schadinsekten
DE69822873D1 (de) Zusammensetzungen und verfahren zur gewichtsverringerung
DE59913665D1 (de) Verfahren zur katalytischen herstellung von substituierten bipyridylderivaten
DE69808303D1 (de) Verfahren zur verbesserung der bioverfügbarkeit des fexofenadins und seiner derivate
DE60032808D1 (de) Verfahren und system zur optimalisierung des gebrauchs der funkverbindung
DE60033941D1 (de) Neuartiges verfahren zur herstellung von l-epi-2-inosose und neuartiges verfahren zur herstellung von epi-inositol
DE69724801D1 (de) Verfahren und zwischenprodukte zur herstellung substituierter chromanolderivate
DE69924489D1 (de) Getreide-beta-glukanzusammensetzungen und verfahren
DE60029697D1 (de) Febrifugin und ispofebrifugin und verfahren zur herstellung der beiden
DE69837100D1 (de) Verfahren zur herstellung von chinolinderivaten
DE69922488D1 (de) Butadienpolymere und verfahren zur herstellung konjugierter dienpolymere
DE69821764D1 (de) Festkörperreiche beschichtungszusammensetzung und verfahren zur decklackierung
DE59806380D1 (de) Verfahren zur Abstandsmessung und Durchführung des Verfahrens
DE69805887D1 (de) Verfahren zur Herstellung von alpha-Bromolactamderivaten
DE60012907D1 (de) Verfahren zur herstellung und zum zusammenbau von schränken und garderoben
DE60022892D1 (de) Verfahren zur Enthaarung
DE69922440D1 (de) Verfahren und Zwischenprodukte zur Herstellung von 2,3-Pyridindicarboxylatderivaten

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
EEIH Change in the person of patent owner